Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults

Abstract

Elevated plasma levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) are related to decreased myocardial vasodilatory capacity and increased risk of acute coronary events. As statin treatment is known to increase nitric oxide bioavailability and enhance myocardial function, we tested whether ADMA concentration modi-fies the effect of pravastatin on myocardial blood flow in young adults with mild hypercholesterolemia. Fifty-one men (35 ± 4 years) were randomly assigned to receive either pravastatin (40 mg/day) or placebo for 6 months. Myocardial blood flow was measured at rest and during adenosine-induced hyperemia using positron emission tomography and oxygen-15-labeled water at baseline and after treatment. Plasma ADMA levels were assessed with high performance liquid chromatography. Low baseline plasma ADMA concentration (< median) predicted a significant improvement of adenosine-induced blood flow after statin intervention (baseline to follow-up change +35%, p = 0.004), whereas high baseline ADMA (≥ median) was associated with no increase in adenosine-induced flow.

Keywords

asymmetric dimethylarginine blood flow positron emission tomography pravastatin

References

Böger RH , Bode-Böger SM , Szuba A et al. Asymmetric dimethylargi-nine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.

Miyazaki H , Matsuoka H , Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.

Vallance P , Leone A , Calver A , Collier J , Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.

Surdacki A , Nowicki M , Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.

Päivä H , Laakso J , Laine H , Laaksonen R , Knuuti J , Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hyper-cholesterolemia. J Am Coll Cardiol 2002; 40: 1241-1247.

Usui M , Matsuoka H , Miyazaki H , Ueda S , Okuda S , Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-2430.

Valkonen VP , Päivä H , Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.

Zoccali C , Bode-Böger S , Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.

Janatuinen T , Laaksonen R , Vesalainen R et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001; 38: 561-568.

10.

Kaesemeyer WH , Caldwell RB , Huang J , Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.

11.

Laufs U , La Fata V , Plutzky J , Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.

12.

Fleck C , Janz A , Schweitzer F , Karge E , Schwertfeger M , Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78: S14-S18.

13.

Ito A , Tsao PS , Adimoolam S , Kimoto M , Ogawa T , Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095.

14.

Stühlinger MC , Tsao PS , Her JH , Kimoto M , Balint RF , Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575.

15.

Iida H , Kanno I , Takahashi A et al. Measurement of absolute myocar-dial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 1988; 78: 104-115.

16.

Iida H , Takahashi A , Tamura Y , Ono Y , Lammertsma AA. Myocardial blood flow: comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation. J Nucl Med 1995; 36: 78-85.

17.

Iida H , Rhodes CG , de Silva R et al. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med 1992; 33: 1669-1677.

18.

Friedewald WT , Levy RI , Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

19.

Lehtimaki T , Lehtinen S , Solakivi T et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 23-27.

20.

Buus NH , Bottcher M , Hermansen F , Sander M , Nielsen TT , Mulvany MJ. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 2001; 104: 2305-2310.